What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?
Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 month...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Desnous, Béatrice [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma - Gieffers, C. ELSEVIER, 2016, Oxford [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:91 ; year:2021 ; pages:503-506 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.seizure.2021.07.032 |
|---|
| Katalog-ID: |
ELV05514229X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV05514229X | ||
| 003 | DE-627 | ||
| 005 | 20230624220055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.seizure.2021.07.032 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica |
| 035 | |a (DE-627)ELV05514229X | ||
| 035 | |a (ELSEVIER)S1059-1311(21)00267-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Desnous, Béatrice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| 264 | 1 | |c 2021 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. | ||
| 700 | 1 | |a Lenoir, Marien |4 oth | |
| 700 | 1 | |a Bitton, Jonathan Y. |4 oth | |
| 700 | 1 | |a Arbour, Mélina |4 oth | |
| 700 | 1 | |a Villeneuve, Nathalie |4 oth | |
| 700 | 1 | |a Whiting, Sharon |4 oth | |
| 700 | 1 | |a Mohammed, Ismail |4 oth | |
| 700 | 1 | |a Wirrell, Elaine C. |4 oth | |
| 700 | 1 | |a Bello-Espinosa, Luis |4 oth | |
| 700 | 1 | |a Ronen, Gabriel M |4 oth | |
| 700 | 1 | |a Lortie, Anne |4 oth | |
| 700 | 1 | |a Birca, Ala |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Gieffers, C. ELSEVIER |t Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |d 2016 |g Oxford [u.a.] |w (DE-627)ELV019641362 |
| 773 | 1 | 8 | |g volume:91 |g year:2021 |g pages:503-506 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.seizure.2021.07.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_252 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 91 |j 2021 |h 503-506 |g 4 | ||
| author_variant |
b d bd |
|---|---|
| matchkey_str |
desnousbatricelenoirmarienbittonjonathan:2021----:htshotmluainovgbtimnteaynainsihnat |
| hierarchy_sort_str |
2021 |
| bklnumber |
44.52 |
| publishDate |
2021 |
| allfields |
10.1016/j.seizure.2021.07.032 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica (DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Desnous, Béatrice verfasserin aut What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? 2021 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. Lenoir, Marien oth Bitton, Jonathan Y. oth Arbour, Mélina oth Villeneuve, Nathalie oth Whiting, Sharon oth Mohammed, Ismail oth Wirrell, Elaine C. oth Bello-Espinosa, Luis oth Ronen, Gabriel M oth Lortie, Anne oth Birca, Ala oth Enthalten in Elsevier Gieffers, C. ELSEVIER Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma 2016 Oxford [u.a.] (DE-627)ELV019641362 volume:91 year:2021 pages:503-506 extent:4 https://doi.org/10.1016/j.seizure.2021.07.032 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 44.52 Therapie Medizin VZ AR 91 2021 503-506 4 |
| spelling |
10.1016/j.seizure.2021.07.032 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica (DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Desnous, Béatrice verfasserin aut What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? 2021 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. Lenoir, Marien oth Bitton, Jonathan Y. oth Arbour, Mélina oth Villeneuve, Nathalie oth Whiting, Sharon oth Mohammed, Ismail oth Wirrell, Elaine C. oth Bello-Espinosa, Luis oth Ronen, Gabriel M oth Lortie, Anne oth Birca, Ala oth Enthalten in Elsevier Gieffers, C. ELSEVIER Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma 2016 Oxford [u.a.] (DE-627)ELV019641362 volume:91 year:2021 pages:503-506 extent:4 https://doi.org/10.1016/j.seizure.2021.07.032 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 44.52 Therapie Medizin VZ AR 91 2021 503-506 4 |
| allfields_unstemmed |
10.1016/j.seizure.2021.07.032 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica (DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Desnous, Béatrice verfasserin aut What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? 2021 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. Lenoir, Marien oth Bitton, Jonathan Y. oth Arbour, Mélina oth Villeneuve, Nathalie oth Whiting, Sharon oth Mohammed, Ismail oth Wirrell, Elaine C. oth Bello-Espinosa, Luis oth Ronen, Gabriel M oth Lortie, Anne oth Birca, Ala oth Enthalten in Elsevier Gieffers, C. ELSEVIER Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma 2016 Oxford [u.a.] (DE-627)ELV019641362 volume:91 year:2021 pages:503-506 extent:4 https://doi.org/10.1016/j.seizure.2021.07.032 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 44.52 Therapie Medizin VZ AR 91 2021 503-506 4 |
| allfieldsGer |
10.1016/j.seizure.2021.07.032 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica (DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Desnous, Béatrice verfasserin aut What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? 2021 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. Lenoir, Marien oth Bitton, Jonathan Y. oth Arbour, Mélina oth Villeneuve, Nathalie oth Whiting, Sharon oth Mohammed, Ismail oth Wirrell, Elaine C. oth Bello-Espinosa, Luis oth Ronen, Gabriel M oth Lortie, Anne oth Birca, Ala oth Enthalten in Elsevier Gieffers, C. ELSEVIER Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma 2016 Oxford [u.a.] (DE-627)ELV019641362 volume:91 year:2021 pages:503-506 extent:4 https://doi.org/10.1016/j.seizure.2021.07.032 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 44.52 Therapie Medizin VZ AR 91 2021 503-506 4 |
| allfieldsSound |
10.1016/j.seizure.2021.07.032 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica (DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.52 bkl Desnous, Béatrice verfasserin aut What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? 2021 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. Lenoir, Marien oth Bitton, Jonathan Y. oth Arbour, Mélina oth Villeneuve, Nathalie oth Whiting, Sharon oth Mohammed, Ismail oth Wirrell, Elaine C. oth Bello-Espinosa, Luis oth Ronen, Gabriel M oth Lortie, Anne oth Birca, Ala oth Enthalten in Elsevier Gieffers, C. ELSEVIER Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma 2016 Oxford [u.a.] (DE-627)ELV019641362 volume:91 year:2021 pages:503-506 extent:4 https://doi.org/10.1016/j.seizure.2021.07.032 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 44.52 Therapie Medizin VZ AR 91 2021 503-506 4 |
| language |
English |
| source |
Enthalten in Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma Oxford [u.a.] volume:91 year:2021 pages:503-506 extent:4 |
| sourceStr |
Enthalten in Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma Oxford [u.a.] volume:91 year:2021 pages:503-506 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |
| authorswithroles_txt_mv |
Desnous, Béatrice @@aut@@ Lenoir, Marien @@oth@@ Bitton, Jonathan Y. @@oth@@ Arbour, Mélina @@oth@@ Villeneuve, Nathalie @@oth@@ Whiting, Sharon @@oth@@ Mohammed, Ismail @@oth@@ Wirrell, Elaine C. @@oth@@ Bello-Espinosa, Luis @@oth@@ Ronen, Gabriel M @@oth@@ Lortie, Anne @@oth@@ Birca, Ala @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019641362 |
| dewey-sort |
3610 |
| id |
ELV05514229X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05514229X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624220055.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.seizure.2021.07.032</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05514229X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1059-1311(21)00267-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Desnous, Béatrice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lenoir, Marien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bitton, Jonathan Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arbour, Mélina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villeneuve, Nathalie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whiting, Sharon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohammed, Ismail</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wirrell, Elaine C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bello-Espinosa, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ronen, Gabriel M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lortie, Anne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birca, Ala</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Gieffers, C. ELSEVIER</subfield><subfield code="t">Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma</subfield><subfield code="d">2016</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV019641362</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:91</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:503-506</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.seizure.2021.07.032</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">91</subfield><subfield code="j">2021</subfield><subfield code="h">503-506</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| author |
Desnous, Béatrice |
| spellingShingle |
Desnous, Béatrice ddc 610 bkl 44.52 What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| authorStr |
Desnous, Béatrice |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019641362 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.52 bkl What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| topic |
ddc 610 bkl 44.52 |
| topic_unstemmed |
ddc 610 bkl 44.52 |
| topic_browse |
ddc 610 bkl 44.52 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m l ml j y b jy jyb m a ma n v nv s w sw i m im e c w ec ecw l b e lbe g m r gm gmr a l al a b ab |
| hierarchy_parent_title |
Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |
| hierarchy_parent_id |
ELV019641362 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019641362 |
| title |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| ctrlnum |
(DE-627)ELV05514229X (ELSEVIER)S1059-1311(21)00267-3 |
| title_full |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| author_sort |
Desnous, Béatrice |
| journal |
Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |
| journalStr |
Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
503 |
| author_browse |
Desnous, Béatrice |
| container_volume |
91 |
| physical |
4 |
| class |
610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Desnous, Béatrice |
| doi_str_mv |
10.1016/j.seizure.2021.07.032 |
| dewey-full |
610 |
| title_sort |
what is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| title_auth |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| abstract |
Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. |
| abstractGer |
Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. |
| abstract_unstemmed |
Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_65 GBV_ILN_70 GBV_ILN_252 |
| title_short |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? |
| url |
https://doi.org/10.1016/j.seizure.2021.07.032 |
| remote_bool |
true |
| author2 |
Lenoir, Marien Bitton, Jonathan Y. Arbour, Mélina Villeneuve, Nathalie Whiting, Sharon Mohammed, Ismail Wirrell, Elaine C. Bello-Espinosa, Luis Ronen, Gabriel M Lortie, Anne Birca, Ala |
| author2Str |
Lenoir, Marien Bitton, Jonathan Y. Arbour, Mélina Villeneuve, Nathalie Whiting, Sharon Mohammed, Ismail Wirrell, Elaine C. Bello-Espinosa, Luis Ronen, Gabriel M Lortie, Anne Birca, Ala |
| ppnlink |
ELV019641362 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.seizure.2021.07.032 |
| up_date |
2024-07-06T16:44:08.932Z |
| _version_ |
1803848776609169408 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05514229X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624220055.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.seizure.2021.07.032</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001918.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05514229X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1059-1311(21)00267-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Desnous, Béatrice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS). Duration of VGB use should be limited because of the risk of retinal and neurotoxicity, but the optimal length of treatment is unknown. Our study aimed to determine the risk of spasms relapse after 6 months of VGB as first-line therapy in IS patients deemed VGB good responders.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lenoir, Marien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bitton, Jonathan Y.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arbour, Mélina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villeneuve, Nathalie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whiting, Sharon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohammed, Ismail</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wirrell, Elaine C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bello-Espinosa, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ronen, Gabriel M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lortie, Anne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birca, Ala</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Gieffers, C. ELSEVIER</subfield><subfield code="t">Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma</subfield><subfield code="d">2016</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV019641362</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:91</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:503-506</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.seizure.2021.07.032</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">91</subfield><subfield code="j">2021</subfield><subfield code="h">503-506</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.3999157 |